Your session is about to expire
← Back to Search
Neurostimulation
Responsive Neurostimulation for PTSD
Verified Trial
Phase < 1
Waitlist Available
Research Sponsored by VA Greater Los Angeles Healthcare System
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Male aged 25-60 years.
Male aged 25-60 years.
Timeline
Screening 7 weeks
Treatment 48 months
Follow Up 36 months
Awards & highlights
No Placebo-Only Group
Summary
This trial uses a device called Responsive Neurostimulation (RNS) to help veterans with severe PTSD who haven't responded to other treatments. The device records brain activity and sends electrical pulses to reduce fear and trauma responses. This approach aims to improve PTSD symptoms by targeting the brain's fear processing mechanisms.
Who is the study for?
This trial is for male veterans aged 25-60 with severe PTSD that hasn't improved after trying at least three different treatments, including medication and psychotherapy. They must have stable health conditions, be on consistent psychotropic medications for two months prior to the study, and live in Southern California for the first year of the trial.
What is being tested?
The NeuroPace® RNS® System is being tested to see if it can help manage PTSD by recording brain signals related to fear and stress from the amygdala. When certain patterns are detected, it sends out electrical pulses aimed at reducing symptoms like flashbacks and nightmares.
What are the potential side effects?
Potential side effects may include discomfort or complications from implant surgery, changes in mood or behavior due to electrical stimulation of the brain, headaches, infection risk at implant site, and possible interference with normal brain function.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am a man aged between 25 and 60.
Timeline
Screening ~ 7 weeks1 visit
Treatment ~ 48 months1 visit
Follow Up ~ 36 months1 visit
Screening ~ 7 weeks
Treatment ~ 48 months
Follow Up ~36 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Alpha rhythm frequency (EEG)
Tomography, Optical Coherence
Region of Interest analysis (FDG PET)
+2 moreSecondary study objectives
Attention, Processing Speed and Memory: Wechsler Adult Intelligence Scale IV (WAIS-IV)143 - Digit Span subtest, Trail Making Test A and B, Ruff Figural Fluency Test (RFFT), Brief Visual Memory Test - Revised (BVMT-R), California Verbal Learning Test
Brief Visual Memory Test
California Verbal Learning Test
+21 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: RNS groupExperimental Treatment1 Intervention
This study consists in only one arm. In this arm, the patients will undergo the placement of the RNS implant and the subsequent RNS programming to optimize the PTSD symptoms.
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Post-Traumatic Stress Disorder (PTSD) treatments often target the neurobiological mechanisms underlying fear and anxiety. Responsive Neurostimulation (RNS) disrupts fear signals in the basolateral amygdala, promoting fear extinction by modulating neural activity associated with trauma reminders.
This is crucial for PTSD patients as it directly addresses the heightened fear response and helps in reducing symptoms. Similarly, SSRIs (Selective Serotonin Reuptake Inhibitors) increase serotonin levels in the brain, which can improve mood and reduce anxiety.
Trauma-focused Cognitive Behavioral Therapy (CBT) helps patients process traumatic memories and reduce avoidance behaviors through exposure and cognitive restructuring. These treatments are essential as they address both the biological and psychological aspects of PTSD, providing a comprehensive approach to symptom management.
PTSD: from neurobiology to pharmacological treatments.
PTSD: from neurobiology to pharmacological treatments.
Find a Location
Logistics
Other reimbursement is provided
Other forms of reimbursement are provided for this trial.
Who is running the clinical trial?
University of California, Los AngelesOTHER
1,569 Previous Clinical Trials
10,314,289 Total Patients Enrolled
VA Greater Los Angeles Healthcare SystemLead Sponsor
52 Previous Clinical Trials
8,678 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- If you started trauma-focused psychotherapy but had to stop because it was too difficult or caused too much emotional pain, you may still be able to participate in the study.The person has had a minimum baseline past month CAPS-5 score of 47, with full PTSD diagnostic criteria met, and scores of ≥ 3 on at least one item from the intrusive (CAPS-5 items 1-5) and hyperarousal (CAPS-5 Items 15-20) clustersI completed PTSD therapy at least 3 months ago.I've been on the same mental health medication for 2 months and won't change it for 6 months, unless needed.If you started trauma-focused therapy but had to stop because it was too intense and caused more harm than good, you may be included in the study.I completed PTSD therapy over 3 months ago.I've tried at least 3 PTSD treatments including medication and therapy without success.I've tried at least 3 treatments for PTSD without success, including medication and therapy.I am a man aged between 25 and 60.I am a man aged between 25 and 60.
Research Study Groups:
This trial has the following groups:- Group 1: RNS group
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 7 Weeks to process to see if you qualify in this trial.
- Treatment: You will receive the treatment for 48 Months
- Follow Ups: You may be asked to continue sharing information regarding the trial for 36 Months after you stop receiving the treatment.
Post-Traumatic Stress Disorder Patient Testimony for trial: Trial Name: NCT04152993 — Phase < 1